11 Apr 2017 Bristol-Myers Squibb and Apexigen, Inc. Announce Clinical Collaboration to Evaluate Opdivo (nivolumab) in Combination with APX005M in Advanced Solid Tumors
11 Apr 2017 Apogenix Announces Initiation of Clinical Development for ABBV-621 to Treat Solid and Hematologic Tumors by Partner AbbVie
10 Apr 2017 Anthera Announces Completion of Dosing in the Phase 2 BRIGHT-SC Study of Blisibimod in Patients with IgA Nephropathy
10 Apr 2017 OncoMed Pharmaceuticals Announces Bayer Terminates its Option to License Vantictumab or Ipafricept
10 Apr 2017 OncoMed's Phase 2 Demcizumab Pancreatic Cancer Trial Misses Primary Endpoint
10 Apr 2017 Alexo Therapeutics Announces Initiation of Phase 1 Clinical Trial of ALX148 for the Treatment of Advanced Solid Tumors and Lymphoma
07 Apr 2017 Regeneron Announces Evinacumab has Received FDA Breakthrough Therapy Designation for Homozygous Familial Hypercholesterolemia (HoFH)
06 Apr 2017 AnaptysBio Announces First-In-Human Dosing of ANB019
06 Apr 2017 Affimed Presents Data on Immune Cell Engager Pipeline at the AACR Annual Meeting 2017
06 Apr 2017 Cascadian Therapeutics Highlights Preclinical Program Presentations at the American Association for Cancer Research Annual Meeting 2017
06 Apr 2017 MabVax Therapeutics Presents Two Posters at the American Association for Cancer Research (AACR) Annual Meeting on a Novel Radioimmunotherapy Treatment for Pancreatic Cancer
05 Apr 2017 TG Therapeutics, Inc. Announces Preclinical Data Presentation on the Company’s Anti-PD-L1 Monoclonal Antibody at the American Association for Cancer Research Annual Meeting
05 Apr 2017 Checkpoint Therapeutics Reports Preclinical Data for Two Oncology Programs
05 Apr 2017 OSE Immunotherapeutics Presented New Data at AACR* Annual Meeting 2017 on OSE-172 (Effi-DEM), Company’s Checkpoint Inhibitor Blocking Suppressive Myeloid Cells and Inducing Antitumoral Potent T Memory Response
05 Apr 2017 Immunomedics Reports Sacituzumab Govitecan (IMMU-132) is Active in Patients With Metastatic Small-Cell Lung Cancer Who Are Sensitive or Resistant to First-Line Chemotherapy
05 Apr 2017 U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application for Opdivo (nivolumab) in Previously Treated dMMR or MSI-H Metastatic Colorectal Cancer
04 Apr 2017 Amgen Submits Applications In The US And Europe To Expand Current Indication For XGEVA® (denosumab) To Include Patients With Multiple Myeloma
04 Apr 2017 Immunomedics Reports Sacituzumab Govitecan (Immu-132) Delivers High Levels of sn-38 That Overcome Chemoresistant Tumors With Moderate to Strong Trop-2 Expression
04 Apr 2017 Siamab Therapeutics Presents New Preclinical Data for Its Novel Anti-STn Antibodies, Antibody-Drug Conjugates, and Anti-STn Bispecific Antibodies at the AACR Annual Meeting 2017
04 Apr 2017 Pieris Pharmaceuticals Presents IND-enabling Data for Bispecific Immuno-Oncology Drug Candidate, PRS-343, in Poster Session at the 2017 Meeting of the American Association for Cancer Research (AACR)
04 Apr 2017 Precision Biologics to Highlight Preclinical Data on NEO-201, a Neoantigen Targeting Antibody in Oral Presentation at the 110th Annual Meeting of the American Association of Clinical Research
04 Apr 2017 Bristol-Myers Squibb Announces Results from CheckMate -143, a Phase 3 Study of Opdivo (nivolumab) in Patients with Glioblastoma Multiforme
04 Apr 2017 OncoMed Presents Preclinical Data for Anti-TIGIT Program at the American Association for Cancer Research Annual Meeting 2017
03 Apr 2017 Leap Therapeutics Presents Non-clinical and Phase 1 Data for TRX518 and DKN-01 at the 2017 AACR Annual Meeting
03 Apr 2017 Trillium Therapeutics Presents TTI-621 Preclinical Data at AACR Annual Meeting and Provides Clinical Update

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing